Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07633756 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07633756: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07633756 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07633756, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
Interventions
- DRUG REC617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-10-19 |
| Est. Completion | 2031-12-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07633756
The ClinicalTrials.gov registry entry for NCT07633756 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REC617 is the first listed.
NCT07633756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07633756 about?
NCT07633756 is a clinical study titled "A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy". To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
What is the current status of trial NCT07633756?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-10-19. Estimated completion is 2031-12-26.
What interventions are being tested in trial NCT07633756?
The interventions under investigation include: REC617 (DRUG).
Who is sponsoring clinical trial NCT07633756?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.